Chinese global biotherapeutics company Transcenta Holding Limited, which had raised an undisclosed equity financing from China Capital Management in June this year, said on Wednesday that it has garnered $105 million in a crossover financing led by China Structural Reform Fund.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
